Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.63. Xtant Medical shares last traded at $0.60, with a volume of 57,742 shares.
Xtant Medical Price Performance
The firm has a market cap of $77.30 million, a price-to-earnings ratio of -60.02 and a beta of 0.36. The company has a quick ratio of 1.01, a current ratio of 2.44 and a debt-to-equity ratio of 0.49.
Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The medical device company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). The firm had revenue of $29.94 million during the quarter. Xtant Medical had a negative net margin of 3.00% and a negative return on equity of 6.71%.
Hedge Funds Weigh In On Xtant Medical
An institutional investor recently raised its position in Xtant Medical stock. Vanguard Group Inc. boosted its stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 3.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,548,312 shares of the medical device company's stock after acquiring an additional 48,319 shares during the quarter. Vanguard Group Inc. owned about 1.19% of Xtant Medical worth $1,812,000 as of its most recent filing with the Securities and Exchange Commission. 69.33% of the stock is currently owned by institutional investors and hedge funds.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Featured Stories
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
